The standard
chemotherapy for
epithelial ovarian cancer (EOC) patients is currently a combination of
taxane and
platinum. However, most EOC patients still suffer relapses, and there is an immediate need for the development of novel and more effective therapeutic modalities against this deadly disease. Recently, the nonpeptide
bradykinin (BK) antagonist 2,3,4,5,6-pentafluorocinnamoyl-(o-2,6-dichlorobenzyl)-l-tyrosine-N-(4-amino-2,2,6,6-tetramethyl-piperidyl)
amide (BKM-570) was shown to cause impressive growth inhibition of lung and prostate
tumors, displaying superior in vivo inhibitory effects than convential chemotherapeutic drugs. Here, we investigated
BKM-570 cytotoxic effects in two EOC cell lines, derived from different EOC histopathologies: a clear cell
carcinoma (TOV-21), and an
endometrioid carcinoma (TOV-112). We showed that
BKM-570 effectively inhibited the growth of
ovarian cancer cells, as its cytotoxic effects were comparable to those of
cisplatin, and were independent of the functional status of BK receptors. Moreover,
BKM-570 synergized with
cisplatin in inhibiting EOC cell growth. To better understand the molecular mechanisms of the antiproliferative action of this BK antagonist in EOC cells, we performed gene expression profiling in TOV-21 and TOV-112 cells following treatment with 10 μM
BKM-570 for 24 h.
BKM-570 displayed similar cytotoxic effects in the two cell lines analyzed, as genes with previously shown involvement in apoptosis/antiapoptosis and cell adhesion were proportionally upregulated and downregulated in both cell lines, whereas genes involved in basic cellular mechanisms, including cell growth and maintenance, metabolism, cell cycle control, inflammatory and immune response, signal transduction, protein biosynthesis, transcription regulation, and transport, were predominantly downregulated upon treatment. Our data are indicative of the therapeutic potential of
BKM-570 and related compounds in EOC management.